{"id":3114,"date":"2025-11-07T11:56:55","date_gmt":"2025-11-07T10:56:55","guid":{"rendered":"https:\/\/www.monitorcm.se\/?p=3114"},"modified":"2025-11-07T11:56:55","modified_gmt":"2025-11-07T10:56:55","slug":"att-kopa-aktier-i-biocrine-ab","status":"publish","type":"post","link":"https:\/\/www.monitorcm.se\/en\/att-kopa-aktier-i-biocrine-ab\/","title":{"rendered":"Buying shares in Biocrine AB"},"content":{"rendered":"<p><span style=\"font-weight: 400;\">Biocrine \u00e4r ett svenskt bioteknikbolag som fokuserar p\u00e5 forskning inom diabetes och dess komplikationer. Bolagets m\u00e5l \u00e4r att kommersialisera nya behandlingskoncept och skapa l\u00f6sningar som m\u00f6jligg\u00f6r kontinuerlig tillf\u00f6rsel av l\u00e4kemedel mot b\u00e5de sjukdomen och dess f\u00f6ljdsjukdomar. Genom avancerad forskning vill Biocrine bidra till b\u00e4ttre livskvalitet f\u00f6r de miljoner m\u00e4nniskor som lever med diabetes v\u00e4rlden \u00f6ver.<\/span><\/p>\n<h2><b>Forskning med fokus p\u00e5 bukspottk\u00f6rteln<\/b><\/h2>\n<p><span style=\"font-weight: 400;\">Diabetes \u00e4r en komplex sjukdom som p\u00e5verkar kroppens \u00e4mnesoms\u00e4ttning och hormonbalans. Det \u00e4r delvis d\u00e4rf\u00f6r som Biocrine bedriver sin forskning med fokus p\u00e5 vad som sker i bukspottk\u00f6rteln, s\u00e4rskilt sammanhanget mellan hormoner, receptorer och molekyler i de s\u00e5 kallade Langerhanska \u00f6arna. Genom att f\u00f6rst\u00e5 dessa processer p\u00e5 molekyl\u00e4r niv\u00e5 kan forskarna identifiera nya angreppspunkter f\u00f6r behandling.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Bolagets forskningsarbete har sin grund i det v\u00e4rldsledande Rolf Luft Research Center for Diabetes and Endocrinology vid Karolinska Institutet. H\u00e4r har professor Per-Olof Berggren och hans team i \u00f6ver tre decennier bedrivit banbrytande forskning om hormonfris\u00e4ttning i den endokrina delen av bukspottk\u00f6rteln. Med hj\u00e4lp av modern biokemi, elektrofysiologi och molekyl\u00e4rbiologi har gruppen gjort flera uppt\u00e4ckter som \u00f6kat f\u00f6rst\u00e5elsen f\u00f6r diabetesutveckling och insulinreglering.<\/span><\/p>\n<h2><b>S\u00e5 kan du investera i Biocrine<\/b><\/h2>\n<p><span style=\"font-weight: 400;\">Biocrine \u00e4r ett onoterat bolag, vilket inneb\u00e4r att aktien inte handlas p\u00e5 n\u00e5gon b\u00f6rs. Via Monitor Capital Markets, som \u00e4r en licensierad m\u00e4klare under Finansinspektionens tillsyn, kan investerare f\u00e5 m\u00f6jlighet att handla aktier i utvalda onoterade bolag inom forskning, medicin och life science. Handeln sker genom matchning av k\u00f6pare och s\u00e4ljare och \u00e4r inte ett offentligt erbjudande.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Att investera i onoterade bolag inneb\u00e4r alltid en h\u00f6gre risk \u00e4n i b\u00f6rsnoterade f\u00f6retag. Likviditeten \u00e4r ofta begr\u00e4nsad och det finns ingen garanti f\u00f6r att investeringen kan s\u00e4ljas eller generera avkastning. Informationen p\u00e5 denna sida utg\u00f6r inte investeringsr\u00e5dgivning utan \u00e4r endast avsedd som allm\u00e4n information. Den som \u00f6verv\u00e4ger att investera b\u00f6r noggrant l\u00e4sa Biocrines publika rapporter och forskningsnyheter samt vid behov r\u00e5dfr\u00e5ga en oberoende finansiell r\u00e5dgivare.<\/span><\/p>\n<p><b>Are you interested in investing?<\/b><\/p>\n<p><a href=\"https:\/\/www.monitorcm.se\/en\/contact\/\"><span style=\"font-weight: 400;\">Contact us<\/span><\/a><span style=\"font-weight: 400;\"> for more information on how to trade and how you can become a shareholder.<\/span><\/p>\n<h3><b>Other unlisted companies investors follow<\/b><\/h3>\n<p><span style=\"font-weight: 400;\"><a href=\"https:\/\/www.monitorcm.se\/en\/handla-aktier-i-a3p-biomedical-ab\/\">A3P Biomedical<\/a> | byWiT | Exeger | Xshore<\/span><\/p>","protected":false},"excerpt":{"rendered":"<p>Biocrine \u00e4r ett svenskt bioteknikbolag som fokuserar p\u00e5 forskning inom diabetes och dess komplikationer. Bolagets m\u00e5l \u00e4r att kommersialisera nya behandlingskoncept och skapa l\u00f6sningar som m\u00f6jligg\u00f6r kontinuerlig tillf\u00f6rsel av l\u00e4kemedel mot b\u00e5de sjukdomen och dess f\u00f6ljdsjukdomar. Genom avancerad forskning vill Biocrine bidra till b\u00e4ttre livskvalitet f\u00f6r de miljoner m\u00e4nniskor som lever med diabetes v\u00e4rlden \u00f6ver. [&#8230;]\n","protected":false},"author":2,"featured_media":3115,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[60],"tags":[],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.6 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Att k\u00f6pa aktier i Biocrine AB &#8211; Monitor Capital Markets<\/title>\n<meta name=\"description\" content=\"Biocrine utvecklar banbrytande behandlingar f\u00f6r diabetes &amp; dess f\u00f6ljdsjukdomar. Svenskt bioteknikbolag med god forskningsbas vid Karolinska Institutet.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.monitorcm.se\/en\/att-kopa-aktier-i-biocrine-ab\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Att k\u00f6pa aktier i Biocrine AB &#8211; Monitor Capital Markets\" \/>\n<meta property=\"og:description\" content=\"Biocrine utvecklar banbrytande behandlingar f\u00f6r diabetes &amp; dess f\u00f6ljdsjukdomar. Svenskt bioteknikbolag med god forskningsbas vid Karolinska Institutet.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.monitorcm.se\/en\/att-kopa-aktier-i-biocrine-ab\/\" \/>\n<meta property=\"og:site_name\" content=\"Monitor Capital Markets\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-07T10:56:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.monitorcm.se\/wp-content\/uploads\/2025\/11\/biorcine.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1000\" \/>\n\t<meta property=\"og:image:height\" content=\"667\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pontus N\u00e4ss\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pontus N\u00e4ss\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.monitorcm.se\/att-kopa-aktier-i-biocrine-ab\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.monitorcm.se\/att-kopa-aktier-i-biocrine-ab\/\"},\"author\":{\"name\":\"Pontus N\u00e4ss\",\"@id\":\"https:\/\/www.monitorcm.se\/#\/schema\/person\/408afedad07610f4f094467bc4010355\"},\"headline\":\"Att k\u00f6pa aktier i Biocrine AB\",\"datePublished\":\"2025-11-07T10:56:55+00:00\",\"dateModified\":\"2025-11-07T10:56:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.monitorcm.se\/att-kopa-aktier-i-biocrine-ab\/\"},\"wordCount\":408,\"publisher\":{\"@id\":\"https:\/\/www.monitorcm.se\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.monitorcm.se\/att-kopa-aktier-i-biocrine-ab\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.monitorcm.se\/wp-content\/uploads\/2025\/11\/biorcine.jpg\",\"articleSection\":[\"Nyheter\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.monitorcm.se\/att-kopa-aktier-i-biocrine-ab\/\",\"url\":\"https:\/\/www.monitorcm.se\/att-kopa-aktier-i-biocrine-ab\/\",\"name\":\"Att k\u00f6pa aktier i Biocrine AB &#8211; Monitor Capital Markets\",\"isPartOf\":{\"@id\":\"https:\/\/www.monitorcm.se\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.monitorcm.se\/att-kopa-aktier-i-biocrine-ab\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.monitorcm.se\/att-kopa-aktier-i-biocrine-ab\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.monitorcm.se\/wp-content\/uploads\/2025\/11\/biorcine.jpg\",\"datePublished\":\"2025-11-07T10:56:55+00:00\",\"dateModified\":\"2025-11-07T10:56:55+00:00\",\"description\":\"Biocrine utvecklar banbrytande behandlingar f\u00f6r diabetes & dess f\u00f6ljdsjukdomar. Svenskt bioteknikbolag med god forskningsbas vid Karolinska Institutet.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.monitorcm.se\/att-kopa-aktier-i-biocrine-ab\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.monitorcm.se\/att-kopa-aktier-i-biocrine-ab\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.monitorcm.se\/att-kopa-aktier-i-biocrine-ab\/#primaryimage\",\"url\":\"https:\/\/www.monitorcm.se\/wp-content\/uploads\/2025\/11\/biorcine.jpg\",\"contentUrl\":\"https:\/\/www.monitorcm.se\/wp-content\/uploads\/2025\/11\/biorcine.jpg\",\"width\":1000,\"height\":667,\"caption\":\"k\u00f6p aktier i biocrine\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.monitorcm.se\/att-kopa-aktier-i-biocrine-ab\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\/\/www.monitorcm.se\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Att k\u00f6pa aktier i Biocrine AB\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.monitorcm.se\/#website\",\"url\":\"https:\/\/www.monitorcm.se\/\",\"name\":\"Monitor Capital Markets\",\"description\":\"Finansiellt M\u00e4kleri med fokus p\u00e5 onoterade bolag och aktier\",\"publisher\":{\"@id\":\"https:\/\/www.monitorcm.se\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.monitorcm.se\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.monitorcm.se\/#organization\",\"name\":\"Monitor Capital Markets\",\"url\":\"https:\/\/www.monitorcm.se\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.monitorcm.se\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.monitorcm.se\/wp-content\/uploads\/2018\/08\/monitor_capital_markets_logo.png\",\"contentUrl\":\"https:\/\/www.monitorcm.se\/wp-content\/uploads\/2018\/08\/monitor_capital_markets_logo.png\",\"width\":720,\"height\":120,\"caption\":\"Monitor Capital Markets\"},\"image\":{\"@id\":\"https:\/\/www.monitorcm.se\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.linkedin.com\/company\/monitor-capital-markets\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.monitorcm.se\/#\/schema\/person\/408afedad07610f4f094467bc4010355\",\"name\":\"Pontus N\u00e4ss\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Att k\u00f6pa aktier i Biocrine AB &#8211; Monitor Capital Markets","description":"Biocrine utvecklar banbrytande behandlingar f\u00f6r diabetes & dess f\u00f6ljdsjukdomar. Svenskt bioteknikbolag med god forskningsbas vid Karolinska Institutet.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.monitorcm.se\/en\/att-kopa-aktier-i-biocrine-ab\/","og_locale":"en_US","og_type":"article","og_title":"Att k\u00f6pa aktier i Biocrine AB &#8211; Monitor Capital Markets","og_description":"Biocrine utvecklar banbrytande behandlingar f\u00f6r diabetes & dess f\u00f6ljdsjukdomar. Svenskt bioteknikbolag med god forskningsbas vid Karolinska Institutet.","og_url":"https:\/\/www.monitorcm.se\/en\/att-kopa-aktier-i-biocrine-ab\/","og_site_name":"Monitor Capital Markets","article_published_time":"2025-11-07T10:56:55+00:00","og_image":[{"width":1000,"height":667,"url":"https:\/\/www.monitorcm.se\/wp-content\/uploads\/2025\/11\/biorcine.jpg","type":"image\/jpeg"}],"author":"Pontus N\u00e4ss","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Pontus N\u00e4ss","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.monitorcm.se\/att-kopa-aktier-i-biocrine-ab\/#article","isPartOf":{"@id":"https:\/\/www.monitorcm.se\/att-kopa-aktier-i-biocrine-ab\/"},"author":{"name":"Pontus N\u00e4ss","@id":"https:\/\/www.monitorcm.se\/#\/schema\/person\/408afedad07610f4f094467bc4010355"},"headline":"Att k\u00f6pa aktier i Biocrine AB","datePublished":"2025-11-07T10:56:55+00:00","dateModified":"2025-11-07T10:56:55+00:00","mainEntityOfPage":{"@id":"https:\/\/www.monitorcm.se\/att-kopa-aktier-i-biocrine-ab\/"},"wordCount":408,"publisher":{"@id":"https:\/\/www.monitorcm.se\/#organization"},"image":{"@id":"https:\/\/www.monitorcm.se\/att-kopa-aktier-i-biocrine-ab\/#primaryimage"},"thumbnailUrl":"https:\/\/www.monitorcm.se\/wp-content\/uploads\/2025\/11\/biorcine.jpg","articleSection":["Nyheter"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.monitorcm.se\/att-kopa-aktier-i-biocrine-ab\/","url":"https:\/\/www.monitorcm.se\/att-kopa-aktier-i-biocrine-ab\/","name":"Att k\u00f6pa aktier i Biocrine AB &#8211; Monitor Capital Markets","isPartOf":{"@id":"https:\/\/www.monitorcm.se\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.monitorcm.se\/att-kopa-aktier-i-biocrine-ab\/#primaryimage"},"image":{"@id":"https:\/\/www.monitorcm.se\/att-kopa-aktier-i-biocrine-ab\/#primaryimage"},"thumbnailUrl":"https:\/\/www.monitorcm.se\/wp-content\/uploads\/2025\/11\/biorcine.jpg","datePublished":"2025-11-07T10:56:55+00:00","dateModified":"2025-11-07T10:56:55+00:00","description":"Biocrine utvecklar banbrytande behandlingar f\u00f6r diabetes & dess f\u00f6ljdsjukdomar. Svenskt bioteknikbolag med god forskningsbas vid Karolinska Institutet.","breadcrumb":{"@id":"https:\/\/www.monitorcm.se\/att-kopa-aktier-i-biocrine-ab\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.monitorcm.se\/att-kopa-aktier-i-biocrine-ab\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.monitorcm.se\/att-kopa-aktier-i-biocrine-ab\/#primaryimage","url":"https:\/\/www.monitorcm.se\/wp-content\/uploads\/2025\/11\/biorcine.jpg","contentUrl":"https:\/\/www.monitorcm.se\/wp-content\/uploads\/2025\/11\/biorcine.jpg","width":1000,"height":667,"caption":"k\u00f6p aktier i biocrine"},{"@type":"BreadcrumbList","@id":"https:\/\/www.monitorcm.se\/att-kopa-aktier-i-biocrine-ab\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/www.monitorcm.se\/"},{"@type":"ListItem","position":2,"name":"Att k\u00f6pa aktier i Biocrine AB"}]},{"@type":"WebSite","@id":"https:\/\/www.monitorcm.se\/#website","url":"https:\/\/www.monitorcm.se\/","name":"Monitor Capital Markets","description":"Financial Brokerage with focus on unlisted companies and shares","publisher":{"@id":"https:\/\/www.monitorcm.se\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.monitorcm.se\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.monitorcm.se\/#organization","name":"Monitor Capital Markets","url":"https:\/\/www.monitorcm.se\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.monitorcm.se\/#\/schema\/logo\/image\/","url":"https:\/\/www.monitorcm.se\/wp-content\/uploads\/2018\/08\/monitor_capital_markets_logo.png","contentUrl":"https:\/\/www.monitorcm.se\/wp-content\/uploads\/2018\/08\/monitor_capital_markets_logo.png","width":720,"height":120,"caption":"Monitor Capital Markets"},"image":{"@id":"https:\/\/www.monitorcm.se\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/monitor-capital-markets\/"]},{"@type":"Person","@id":"https:\/\/www.monitorcm.se\/#\/schema\/person\/408afedad07610f4f094467bc4010355","name":"Pontus N\u00e4ss"}]}},"_links":{"self":[{"href":"https:\/\/www.monitorcm.se\/en\/wp-json\/wp\/v2\/posts\/3114"}],"collection":[{"href":"https:\/\/www.monitorcm.se\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.monitorcm.se\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.monitorcm.se\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.monitorcm.se\/en\/wp-json\/wp\/v2\/comments?post=3114"}],"version-history":[{"count":1,"href":"https:\/\/www.monitorcm.se\/en\/wp-json\/wp\/v2\/posts\/3114\/revisions"}],"predecessor-version":[{"id":3116,"href":"https:\/\/www.monitorcm.se\/en\/wp-json\/wp\/v2\/posts\/3114\/revisions\/3116"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.monitorcm.se\/en\/wp-json\/wp\/v2\/media\/3115"}],"wp:attachment":[{"href":"https:\/\/www.monitorcm.se\/en\/wp-json\/wp\/v2\/media?parent=3114"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.monitorcm.se\/en\/wp-json\/wp\/v2\/categories?post=3114"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.monitorcm.se\/en\/wp-json\/wp\/v2\/tags?post=3114"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}